European Union - English - EMA (European Medicines Agency)

therakind (europe) limited - methotrexate - arthritis, psoriatic; precursor cell lymphoblastic leukemia-lymphoma; psoriasis; arthritis, rheumatoid; arthritis - antineoplastic agents - in rheumatological and dermatological diseasesactive rheumatoid arthritis in adult patients.polyarthritic forms of active, severe juvenile idiopathic arthritis (jia) in adolescents and children aged 3 years and over when the response to non-steroidal anti-inflammatory drugs (nsaids) has been inadequate.severe, treatment-refractory, disabling psoriasis which does not respond sufficiently to other forms of treatment such as phototherapy, psoralen and ultraviolet a radiation (puva) therapy and retinoids, and severe psoriatic arthritis in adult patients.in oncologymaintenance treatment of acute lymphoblastic leukaemia (all) in adults, adolescents and children aged 3 years and over.

European Union - English - EMA (European Medicines Agency)

roche registration gmbh - tocilizumab - arthritis, rheumatoid; arthritis, juvenile rheumatoid; cytokine release syndrome; giant cell arteritis; covid-19 virus infection - immunosuppressants - roactemra, in combination with methotrexate (mtx), is indicated forthe treatment of severe, active and progressive rheumatoid arthritis (ra) in adults not previously treated with mtx.the treatment of moderate to severe active ra in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (dmards) or tumour necrosis factor (tnf) antagonists.in these patients, roactemra can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate.roactemra has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function when given in combination with methotrexate.roactemra is indicated for the treatment of active systemic juvenile idiopathic arthritis (sjia) in patients 1 year of age and older, who have responded inadequately to previous therapy with nsaids and systemic corticosteroids. roactemra can be given as monotherapy (in case of intolerance to mtx or where treatment with mtx is inappropriate) or in combination with mtx.roactemra in combination with methotrexate (mtx) is indicated for the treatment of juvenile idiopathic polyarthritis (pjia; rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with mtx.  roactemra can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate.roactemra is indicated for the treatment of giant cell arteritis (gca) in adult patients.roactemra, in combination with methotrexate (mtx), is indicated for:the treatment of severe, active and progressive rheumatoid arthritis (ra) in adults not previously treated with mtx.the treatment of moderate to severe active ra in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (dmards) or tumour necrosis factor (tnf) antagonists.in these patients, roactemra can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. roactemra has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function when given in combination with methotrexate.roactemra is indicated for the treatment of coronavirus disease 2019 (covid-19) in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation.roactemra is indicated for the treatment of active systemic juvenile idiopathic arthritis (sjia) in patients 2 years of age and older, who have responded inadequately to previous therapy with nsaids and systemic corticosteroids. roactemra can be given as monotherapy (in case of intolerance to mtx or where treatment with mtx is inappropriate) or in combination with mtx.roactemra in combination with methotrexate (mtx) is indicated for the treatment of juvenile idiopathic polyarthritis (pjia; rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with mtx. roactemra can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate.roactemra is indicated for the treatment of chimeric antigen receptor (car) t cell-induced severe or life-threatening cytokine release syndrome (crs) in adults and paediatric patients 2 years of age and older.roactemra, in combination with methotrexate (mtx), is indicated for:the treatment of severe, active and progressive rheumatoid arthritis (ra) in adults not previously treated with mtx.the treatment of moderate to severe active ra in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (dmards) or tumour necrosis factor (tnf) antagonists.in these patients, roactemra can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. roactemra has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function when given in combination with methotrexate.roactemra is indicated for the treatment of coronavirus disease 2019 (covid-19) in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation.roactemra is indicated for the treatment of active systemic juvenile idiopathic arthritis (sjia) in patients 2 years of age and older, who have responded inadequately to previous therapy with nsaids and systemic corticosteroids. roactemra can be given as monotherapy (in case of intolerance to mtx or where treatment with mtx is inappropriate) or in combination with mtx.roactemra in combination with methotrexate (mtx) is indicated for the treatment of juvenile idiopathic polyarthritis (pjia; rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with mtx. roactemra can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate.roactemra is indicated for the treatment of chimeric antigen receptor (car) t cell-induced severe or life-threatening cytokine release syndrome (crs) in adults and paediatric patients 2 years of age and older.

European Union - English - EMA (European Medicines Agency)

sanofi winthrop industrie - sarilumab - arthritis, rheumatoid - immunosuppressants - kevzara in combination with methotrexate (mtx) is indicated for the treatment of moderately to severely active rheumatoid arthritis (ra) in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (dmards). kevzara can be given as monotherapy in case of intolerance to mtx or when treatment with mtx is inappropriate.

European Union - English - EMA (European Medicines Agency)

sandoz gmbh - rituximab - lymphoma, non-hodgkin; arthritis, rheumatoid; leukemia, lymphocytic, chronic, b-cell; wegener granulomatosis; microscopic polyangiitis; pemphigus - antineoplastic agents - rixathon is indicated in adults for the following indications:non-hodgkin’s lymphoma (nhl)rixathon is indicated for the treatment of previously untreated adult patients with stage iii-iv follicular lymphoma in combination with chemotherapy.rixathon maintenance therapy is indicated for the treatment of adult follicular lymphoma patients responding to induction therapy.rixathon monotherapy is indicated for treatment of adult patients with stage iii-iv follicular lymphoma who are chemoresistant or are in their second or subsequent relapse after chemotherapy.rixathon is indicated for the treatment of adult patients with cd20 positive diffuse large b cell non-hodgkin’s lymphoma in combination with chop (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy.rixathon in combination with chemotherapy is indicated for the treatment of paediatric patients (aged ≥ 6 months to < 18 years old) with previously untreated advanced stage cd20 positive diffuse large b-cell lymphoma (dlbcl), burkitt lymphoma (bl)/burkitt leukaemia (mature b-cell acute leukaemia) (bal) or burkitt-like lymphoma (bll).chronic lymphocytic leukaemia (cll)rixathon in combination with chemotherapy is indicated for the treatment of patients with previously untreated and relapsed/refractory chronic lymphocytic leukaemia. only limited data are available on efficacy and safety for patients previously treated with monoclonal antibodies including rituximab or patients refractory to previous rituximab plus chemotherapy.see section 5.1 for further information.rheumatoid arthritisrixathon in combination with methotrexate is indicated for the treatment of adult patients with severe active rheumatoid arthritis who have had an inadequate response or intolerance to other disease modifying anti-rheumatic drugs (dmard) including one or more tumour necrosis factor (tnf) inhibitor therapies.rituximab has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function, when given in combination with methotrexate.granulomatosis with polyangiitis and microscopic polyangiitisrixathon, in combination with glucocorticoids, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (wegener’s) (gpa) and microscopic polyangiitis (mpa).rixathon, in combination with glucocorticoids, is indicated for the induction of remission in paediatric patients (aged ≥ 2 to < 18 years old) with severe, active gpa (wegener’s) and mpa.pemphigus vulgarisrixathon is indicated for the treatment of patients with moderate to severe pemphigus vulgaris (pv).

Singapore - English - HSA (Health Sciences Authority)

abbott laboratories (singapore ) private limited - clinical chemistry - the rheumatoid factor (rf) assay is used for the quantitation of rheumatoid factor in human serum.

Singapore - English - HSA (Health Sciences Authority)

beckman coulter singapore pte. ltd. - immunology - rf reagent, when used in conjunction with immage® immunochemistry systems and calibrator 5 plus, is intended for the quantitative determination of rheumatoid factor (rf) in human serum or plasma by rate nephelometry.

Singapore - English - HSA (Health Sciences Authority)

bio-rad laboratories (singapore) pte ltd - immunology - bio-rad liquichek rheumatoid factor control is intended to use as an assayed control serum to monitor the precision of laboratory procedures for rheumatoid factor testing.

Singapore - English - HSA (Health Sciences Authority)

sebia singapore pte ltd - immunology - an elisa-based test system for the quantitative measurement of igg, iga and igm class rheumatoid factor (rf) in human serum or plasma samples. this product is intended for professional in vitro diagnostic use only.

Singapore - English - HSA (Health Sciences Authority)

sebia singapore pte ltd - immunology - an indirect solid phase enzyme immunoassay (elisa) for the quantitative measurement of igg, igm and iga class rheumatoid factor antibodies in human serum or plasma (citrate plasma, na-heparin plasma, edta plasma). the assay is intended for in vitro diagnostic use only as an aid in the diagnosis of rheumatoid arthritis (ra).

Singapore - English - HSA (Health Sciences Authority)

roche diagnostics asia pacific pte ltd - clinical chemistry - in vitro test for the quantitative determination of rheumatoid factors (rf‑ii) in human serum and plasma on roche/hitachi cobas c systems. measurements may be used as an aid in the diagnosis of rheumatoid arthritis.